Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following are excluded:
• •Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
• •A history of allergy to or intolerance of imidazoles or azoles.
• •Moderate or severe liver disease defined by specified lab values.
• •Life expectancy of \< 2 weeks.
• •Concurrent Medication:
• •Excluded:
• •Coumarin-type anticoagulants.
• •Oral hypoglycemics.
• •Barbiturates.
• •Phenytoin.
• •Immunostimulants.
• •Investigational drugs or approved (licensed) drugs for investigational indications except aerosolized pentamidine.
• •Concurrent Treatment:
• •Excluded:
• •Lymphocyte replacement.
• •Patients with the following are excluded:
• •Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
• •A history of allergy to or intolerance of imidazoles or azoles.
• •Moderate or severe liver disease defined by specified lab values.
• •Life expectancy of \< 2 weeks.
• •Prior Medication:
• •Excluded:
• •Coumarin-type anticoagulants.
• •Oral hypoglycemics.
• •Barbiturates.
• •Phenytoin.
• •Immunostimulants.
• •Investigational drugs or approved (licensed) drugs for investigational indications except aerosolized pentamidine.
• •Prior Treatment:
• •Excluded:
• •Lymphocyte replacement.